Video

Dr John C. Morris Highlights Exciting Developments in Lung Cancer Immunotherapy

The introduction of the immune regulatory checkpoint inhibitors and their impressive results is what John C. Morris, MD, professor of hematology and oncology at the University of Cincinnati, finds most exciting in the area of lung cancer immunotherapy.

The introduction of the immune regulatory checkpoint inhibitors and their impressive results is what John C. Morris, MD, professor of hematology and oncology at the University of Cincinnati, finds most exciting in the area of lung cancer immunotherapy.

Ongoing studies are using these inhibitors in combination with each other and with cancer vaccines. Early results of one of his own clinical trials of the HyperAcute lung vaccine has shown the vaccine to be safe and that very heavily pre-treated patients may benefit from it,

"The results will be very interesting if it shakes out that the vaccine has results that are either equal to or better than the standard of care," Dr Morris said. He added, "Chemotherapy has the typical chemotherapy side effects; the vaccine has had none of these side effects."

Related Videos
Marla Black Morgan, MD, Phoebe Neurology Associates
Toby Maher, MD, PhD, professor of clinical medicine, Keck School of Medicine at USC
Nini Wu, MD, Navista
Matthew Viggiano, MD, internal medicine resident, Temple University Hospital
Krunal Patel, MD, pulmonary and critical care fellow, Temple University Hospital
M. Bradley Drummond, MD, MHS, professor of medicine, University of North Carolina at Chapel Hill
Sanjay Ramakrishnan, MD, senior lecturer, University of Western Australia
Michael Goulet, DO, pulmonary and critical care fellow, Temple University Hospital
Tom Belmon, CAP, GPBCH
Constance Blunt, MD, medical oncologist, Mary Bird Perkins Cancer Center
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo